Evolva India moves to Chennai
Evolva Biotech Private Limited (“Evolva India”) is a majority-owned subsidiary of the Evolva group. The unit works on the creation of gene libraries and synthetic and analytical chemistry. In addition, it works on industrial projects and informatics. At the end of 2009, the unit employed 23 people. Evolva India has recently moved from Hyderabad to the Ticel Bio Park in Chennai.
The Ticel Bio Park is a one of a kind exclusive Bio Tech Park and is a unit of TIDCO (Tamilnadu Industrial Development Corporation Limited) and a State Government undertaking. It has world class lab infrastructure and has been in operations since 2004. The tenancy area and the training center are some of the unique features of this park. Cornell University, USA has provided the design and the technical parameters. The main advantage of this Bio Park is its location in the “Knowledge Corridor “ where leading IT firms & institutions of high tech research are situated and is also in the vicinity of residential areas. It is easily accessible and is located at around 14 km from the International Airport and 16 km from Chennai Sea Port.
Chennai is the capital of Tamil Nadu and is the 4th largest city in the country. It is the 34th largest metropolitan area in the world and has the 2nd longest seashore in the world popularly known as the “Marina” beach stretching to around 12 km. Chennai’s economy has a broad industrial base in car manufacturing, technology & hardware manufacturing and healthcare industries. A number of car manufacturing units of Hyundai, Ford, BMW, Mitsubishi, Nissan-Renault, TVS, Ashok Leyland are based in Chennai. This provides a number of job opportunities for many aspiring and budding professionals. The HVF (Heavy Vehicles Factory) in Chennai produces military vehicles for the country and also manufactures railway coaches for the Indian Railways. Chennai accounts for around 60% of the country’s automotive exports. This very industrial expanse has given Chennai the name of “Detroit of South Asia”.
The city is India’s 2nd largest exporter of software, information technology and ITES. Dell has its manufacturing unit near Chennai. The presence of Wipro, Infosys, Acenture, Satyam, and Polaris in the city makes it another major software hub in India. We are now in the same vicinity where all these giants have their offices which is, as already mentioned is more popularly known as the “Knowledge Corridor” of Chennai. Telecom giants of the likes of Ericsson, Nokia, Motorola and Alcatel Lucent are also based in India in Chennai.
Large pharma and chemical companies like Pfizer, Dow Chemicals and Orchid Chemicals have their R&D facilities in the city. In the healthcare domain, Chennai boasts of having Apollo hospitals, which is the largest private Healthcare Provider in Asia. Apart from this, the “Sankara Nethralaya Eye Hospitals “ & The Ramachandra Medical College & Hospitals makes Chennai the most preferred destination for medical tourists from around the globe.
Chennai is also famous for its high-quality educational institutions. Premiere centers for education being the IIT, Anna University and many well known Engineering Colleges. Realising the importance of education research in animal and fisheries sciences so as to increase its productivity towards better income generation for farmers, the Government of Tamil Nadu established the first Veterinary College which was the first of its kind to be affiliated to the University of Madras. The Tamil Nadu Agricultural University is the world’s largest and top most Agricultural University. The primary objective of which is to serve for the betterment of the farming community. It is a resourceful institute to many parts of India and has 34 research stations for agro technology.
For the location of the new premises, please see www.evolva.com under “Contact us”.
The new contact details of Evolva India are:
Evolva Biotech Private Limited
401 – 405, 4th Floor
Ticel Bio Park Ltd
Taramani Road, Taramani
Chennai 600 113
Tamil Nadu, India
Tel: +91 44 4297 1050
Fax: +91 44 4297 1060
Download PDF
About Evolva Holding SA
Evolva's proprietary discovery technology platform uses a “disruptive” technological approach to the creation of novel small compounds that differs sharply from the prevailing synthetic chemistry and protein engineering approaches in the pharmaceutical industry today. Based on this technology, Evolva has a number of discovery and pre-clinical partnerships which in 2009 generated revenues of CHF 18.9 million. Evolva also has an attractive pipeline of compounds – one drug candidate (for renal and cardiovascular diseases) entered Phase I at the beginning of 2009, and two others (an anti-fungal and an anti-viral) are in late preclinical stages. Evolva is listed in the main standard of the SIX Swiss Exchange with the ticker EVE. For more information see www.evolva.com.